HTCR HeartCore Enterprises, Inc.

CIK 0001892322 49 ready 8-Ks latest May 15, 2026, 8:30 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 2 baseline

Ready 8-Ks 49

Latest filing May 15, 2026, 8:30 AM ET

Top materiality 0.85

Event mix other_material ×18 · earnings ×12 · regulatory ×10

Sentiment 21 pos · 10 neg · 18 neu

Latest earnings reported 2025-FY

Recent 8-K filings for HTCR

Highest-materiality recent filing

HeartCore Q3 revenue $17.9M (+281% YoY), net income $10.8M vs loss a year ago

November 14, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Q3 revenue $17.9M (+281% YoY); net income $10.8M ($0.53 diluted EPS) vs net loss of $2.5M a year ago.
Gross profit surged 1,640% to $14.4M; operating expenses fell to $2.3M from $2.6M.

Read filing →

May 15, 2026, 8:30 AM ET earnings materiality 0.55 negative item 2.02 item 9.01

HeartCore Q1 revenue down 43% to $1.2M; net loss narrows to $2.0M

Revenue of $1.2M, down 43% YoY from $2.1M due to decline in software development and services.
April 22, 2026, 7:59 PM ET regulatory materiality 0.65 positive item 7.01 item 8.01 item 9.01

HeartCore regains Nasdaq minimum bid price compliance, listing continues

Received Nasdaq notice on April 20, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
April 6, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.03 item 9.01 ◈ Governance Changes

HeartCore Enterprises executes 1-for-20 reverse stock split, effective April 2, 2026

Board approved 1-for-20 reverse stock split on March 4, 2026; effective for state law at 4:00 PM ET on April 2, 2026.
April 1, 2026, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

HeartCore Enterprises announces 1-for-20 reverse stock split to regain Nasdaq compliance

Reverse split ratio set at 1-for-20; effective April 2, 2026 at 4:00 p.m. ET.
March 31, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

HeartCore FY2025 rev $9.0M (-60% YoY); net income $5.5M on gain from divestiture

Revenue $9.0M vs $22.7M YoY; prior year included $13M warrant revenue from a large Go IPO deal.
March 27, 2026, 7:59 PM ET other materiality 0.15 neutral item 5.03 item 9.01 ◈ Governance Changes

HeartCore amends bylaws to clarify attorneys' fees provision excludes internal corporate claims

Board adopted amendment to Section 7.4 of Bylaws on March 24, 2026.
February 24, 2026, 6:59 PM ET other material materiality 0.55 positive item 7.01 item 8.01 item 9.01

HeartCore authorizes $2M share repurchase; net assets exceed market cap

Board authorized repurchase of up to $2.0M of common stock via open market, private deals, or 10b5-1 plans.
February 11, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

HeartCore preliminary FY2025 revenue $8.5M-$9.5M, net income $3.0M-$4.0M, driven by $7M gain on Japan divestiture

Revenue expected $8.5M-$9.5M, down YoY due to divestiture of HeartCore Japan; prior year net loss of $5.2M.
November 18, 2025, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

HeartCore Q3 revenue falls to $3M, net income $0.4M after divesting software unit

Q3 2025 revenue $3.0M vs $16.2M prior year; prior year included $13M warrant revenue from large Go IPO deal.
November 10, 2025, 6:59 PM ET regulatory materiality 0.50 neutral item 7.01 item 8.01 item 9.01

HeartCore gets 180-day Nasdaq extension to May 1, 2026 for $1 minimum bid compliance

Nasdaq granted until May 1, 2026 to regain $1.00 minimum bid price compliance; prior deadline was Nov 3, 2025.
November 4, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 1.01 item 2.01 item 7.01 item 8.01 item 9.01 ◈ M&A Transactions

HeartCore clarifies post-sale equity over $5M; shifts strategy to Go IPO consulting

Sale of HeartCore Japan closed Oct 31 for ¥1.8B (~$12M), with deferred consideration of ¥387M at 6.65% interest due Oct 2028.
October 31, 2025, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 2.01 item 7.01 item 8.01 item 9.01 ◈ M&A Transactions

HeartCore sells software subsidiary for ~$12M; shifts to Go IPO consulting

Sold HeartCore Japan to Volaris Group for ¥1.8B (~$12M) in all-cash; closed Oct 31, 2025.
October 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

HeartCore clarifies one-time $0.13/share payment as distribution, not dividend; record Nov 10, pay Nov 17

One-time payment of $0.13/share classified as a distribution for U.S. federal tax purposes, correcting earlier dividend statement.
October 20, 2025, 7:59 PM ET dividend materiality 0.65 positive item 7.01 item 8.01 item 9.01

HeartCore declares $0.13/share one-time dividend, ~17.8% of stock price, payable Nov 17

One-time dividend of $0.13 per share authorized by Board on October 19, 2025.
September 26, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07 item 9.01

HeartCore stockholders elect five director nominees and ratify auditor at 2025 annual meeting

All five nominees elected: Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Yoonji Lee, Koji Sato.
August 28, 2025, 7:59 PM ET regulatory materiality 0.55 positive item 7.01 item 8.01 item 9.01

HeartCore regains Nasdaq minimum equity compliance after Q2 equity of $3.56M

Nasdaq notified HeartCore on Aug 19, 2025 that it regained compliance with the $2.5M minimum stockholders' equity rule.
August 18, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

HeartCore announces Go IPO client rYojbaba begins Nasdaq trading; warrants valued at ~$1.35M

rYojbaba (RYOJ) commenced trading on Nasdaq Capital Market on August 18, 2025.
August 14, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02

HeartCore director Heather Neville and CSO Prakash Sadasivam resign, effective Sept 1 and Aug 31 respectively

Director Heather Neville resigns effective September 1, 2025; not due to any disagreement.
August 13, 2025, 7:59 PM ET earnings materiality 0.55 positive item 2.02 item 9.01

HeartCore returns to profitability with Q2 net income $1.1M; revenue up 16.7%

Revenue $4.7M (+16.7% YoY); gross profit $2.2M (+175.2%).
July 17, 2025, 7:59 PM ET regulatory materiality 0.60 negative item 8.01

HeartCore gets Nasdaq extension to Sept 30 to meet $2.5M equity requirement via $25M ELOC and $2M preferred

Nasdaq granted extension until September 30, 2025 to regain compliance with $2,500,000 minimum stockholders' equity requirement.
July 7, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 5.03 item 5.07 item 7.01 item 9.01 ◈ Governance Changes

HeartCore enters $25M equity line with Crom, issues $2M Series A preferred, stockholder approves reverse split

Equity Purchase Agreement with Crom for up to $25M in common stock (ELOC); $250K commitment fee in shares.
July 2, 2025, 7:59 PM ET other material materiality 0.45 positive item 7.01 item 9.01

HeartCore signs 16th Go IPO consulting agreement with Cipher Core for $500K plus warrant

Cipher Core will pay $500,000 in fees plus a warrant for 3% of its fully diluted capital stock.
July 1, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

HeartCore secures up to $27M financing: $25M equity line + $2M convertible preferred from Crom Fund

Equity Purchase Agreement: HeartCore may sell up to $25M of common stock to Crom over 24 months at a discount of 50% of average daily trading volume.
June 30, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 7.01 item 9.01

HeartCore partners with Silver Egg to integrate AI recommend engine into CMS by Aug 2025

OEM agreement signed June 23, 2025, with Silver Egg for its 'Aigent Recommender' AI recommendation service.
June 3, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 7.01 item 9.01

HeartCore signs 15th Go IPO consulting contract with tmsuk; $500k fee plus 3% warrant

Cash fee of $500,000 payable in three installments: $200k at signing, $150k at 3 months, $150k at 6 months.
May 27, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 item 9.01

HeartCore receives Nasdaq delisting notice for failure to meet minimum stockholders' equity requirement

Received Nasdaq Staff notice on May 24, 2025 for non-compliance with $2.5M minimum stockholders' equity requirement (Rule 5550(b)).
May 15, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

HeartCore Q1 revenue falls 28% to $3.6M; net loss widens to $3.1M

Revenue of $3.6M down from $5.0M YoY; on-premise software, Sigmaways, and Go IPO all declined.
May 13, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 item 9.01

HeartCore receives Nasdaq bid price deficiency notice; has 180 days to regain compliance

Received Nasdaq written notice on May 6, 2025 for failure to meet $1.00 minimum bid price requirement.
March 31, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

HeartCore reports 2024 revenue up 39% to $30.4M; net loss attributable improves

FY2024 revenue $30.4M (+39% YoY); gross profit $17.8M (+121% YoY).
March 19, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

HeartCore loses controlled company status; forms compensation and nominating committees

Sumitaka Yamamoto's voting power fell below 50% after ATM sales, triggering loss of controlled company status.
November 15, 2024, 6:59 PM ET other material materiality 0.25 neutral item 7.01 item 9.01

HeartCore furnishes investor presentation; no specific details disclosed in filing

Management will deliver an investor presentation starting November 15, 2024.
November 14, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

HeartCore Q3 revenue $17.9M (+281% YoY), net income $10.8M vs loss a year ago

Q3 revenue $17.9M (+281% YoY); net income $10.8M ($0.53 diluted EPS) vs net loss of $2.5M a year ago.
November 6, 2024, 6:59 PM ET regulatory materiality 0.60 positive item 7.01 item 9.01

HeartCore regains Nasdaq minimum bid price compliance; delisting risk removed

Received Nasdaq notice on Nov 5, 2024 confirming compliance with $1.00 minimum bid price requirement.
November 1, 2024, 7:59 PM ET other materiality 0.60 neutral item 7.01 item 9.01

HeartCore corrects press release: sales growth projection lowered from 115% to 15%

HeartCore expanded its CMS platform to a SaaS delivery model, leveraging AWS infrastructure.
October 29, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 7.01 item 9.01

HeartCore to appeal Nasdaq delisting; preliminary Q3 revenue up 263-305% YoY

Received Nasdaq notice on Oct 22, 2024 for non-compliance with $1 minimum bid price; trading suspended Oct 31 if no appeal.
October 28, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

HeartCore receives Nasdaq delisting notice for bid price non-compliance; intends to appeal

Received Oct 22, 2024 Nasdaq notice for failure to maintain $1.00 minimum bid price for continued listing.
October 18, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

HeartCore preliminary Q3 2024 revenue $17-19M vs $4.7M YoY; net income $9-11M vs loss of $2.5M

Revenue expected $17-19M, up 263-305% YoY; net income $9-11M vs $2.5M loss in Q3 2023.
September 27, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.07 item 9.01

HeartCore shareholders approve reverse stock split authorization at 2024 annual meeting

Six directors elected: Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Heather Neville, Prakash Sadasivam, Koji Sato.
September 25, 2024, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

SBC Medical Group begins trading on Nasdaq; HeartCore guides Q3 rev $19-23M, net profit $4-8M

Go IPO client SBC Medical Group commenced trading on Nasdaq Global Market under symbol 'SBC'.
August 19, 2024, 7:59 PM ET other material materiality 0.50 neutral item 7.01 item 9.01

HeartCore Enterprises projects FY2024 revenue of $46.6M, subject to IPO timing

Projected full-year 2024 revenue of $46.6 million, contingent on Go IPO client IPO timing.
August 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

HeartCore Q2 revenue down 20% to $4.1M, net loss widens to $2.2M; dividend authorized

Net loss of $2.2M ($0.09 diluted EPS) vs net loss of $1.0M ($0.04) in Q2 2023.
July 22, 2024, 7:59 PM ET dividend materiality 0.60 positive item 7.01 item 8.01 item 9.01

HeartCore declares $0.02 per share quarterly dividend, second payment

Second dividend of $0.02 per share, aggregate $417,283; record date Aug 19, payable Aug 26, 2024.
May 15, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

HeartCore Q1 revenue $5.0M (down 43% YoY); net loss $1.5M vs prior year net income $1.8M

Revenue $5.0M vs $8.7M YoY; decline due to lower Go IPO consulting from two clients listing on Nasdaq last year.
May 13, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

HeartCore updates on $9M warrant sale; cash received, revenue deferred until client IPO in Fall 2024

Gross $9M from sale of Go IPO warrant to Japanese financial institution; $5M received Q1 2024, $4M in April.
April 26, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 8.01

HeartCore gets Nasdaq extension to Oct 21, 2024 to cure bid price deficiency

Received Bid Price Notice Oct 26, 2023 for non-compliance with $1.00 minimum bid price.
April 15, 2024, 7:59 PM ET other material materiality 0.65 positive item 2.02 item 7.01 item 9.01

HeartCore signs 14th Go IPO contract with Koei Shoji; $500K fees plus 3% warrant

Signed consulting agreement with Koei Shoji Co., Ltd. to assist in U.S. listing on Nasdaq or NYSE.
April 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

HeartCore FY2023 rev $21.8M (+148%), net loss $4.9M; authorizes dividend, 10 clients in Go IPO pipeline

Revenue $21.8M (+148% YoY); gross profit $8.1M (+140.7%); net loss $4.9M ($0.21/diluted share).
April 1, 2024, 7:59 PM ET dividend materiality 0.55 positive item 7.01 item 8.01 item 9.01

HeartCore declares $0.02/share quarterly dividend; $417k total payout

Quarterly dividend of $0.02 per share, aggregate $417,283 to be paid.
March 18, 2024, 7:59 PM ET other material materiality 0.45 positive item 7.01 item 9.01

HeartCore signs 13th Go IPO consulting deal with PharmaBio; $800k fees plus warrant

Signed 13th Go IPO consulting agreement with PharmaBio Corporation, second contract in 2024.

Earnings & guidance

2025-FY EPS reported $0.22 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

21 positive 10 negative 18 neutral

source · HTCR on sec.gov